Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase

David Mengel1,2*, Wen Liu1, Robert J. Glynn3, Dennis J. Selkoe1, Andre Strydom4,5, Florence Lai6, H. Diana Rosas6,7, Amy Torres8, Vasiliki Patsiogiannis8, Brian Skotko8,9 and Dominic M. Walsh1*

Abstract

Background: Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD), but diagnosis of AD in DS is challenging due to the intellectual disability which accompanies DS. When disease-modifying agents for AD are approved, reliable biomarkers will be required to identify when and how long people with DS should undergo treatment. Three cardinal neuropathological features characterize AD, and AD in DS—Aβ amyloid plaques, tau neurofibrillary tangles, and neuronal loss. Here, we quantified plasma biomarkers of all 3 neuropathological features in a large cohort of people with DS aged from 3 months to 68 years. Our primary aims were (1) to assess changes in the selected plasma biomarkers in DS across age, and (2) to compare biomarkers measured in DS plasma versus age- and sex-matched controls.

Methods: Using ultra-sensitive single molecule array (Simoa) assays, we measured 3 analytes (Aβ42, NfL, and tau) in plasmas of 100 individuals with DS and 100 age- and sex-matched controls. Tau was measured using an assay (NT1) which detects forms of tau containing at least residues 6–198. The stability of the 3 analytes was established using plasma from ten healthy volunteers collected at 6 intervals over a 5-day period.

Results: High Aβ42 and NT1 tau and low NfL were observed in infants. Across all ages, Aβ42 levels were higher in DS than controls. Levels of Aβ42 decreased with age in both DS and controls, but this decrease was greater in DS than controls and became prominent in the third decade of life. NT1 tau fell in adolescents and young adults, but increased in older individuals with DS. NfL levels were low in infants, children, adolescents, and young adults, but thereafter increased in DS compared to controls.

(Continued on next page)
Introduction
Trisomy of chromosome 21, commonly known as Down syndrome (DS), is the most common genetic cause of lifelong intellectual disability and occurs in over 7 million people worldwide [1]. DS is also the most common genetic cause of early onset Alzheimer’s disease (AD) [2], and in prospective studies, the cumulative incidence for dementia is around 90% [3–5]. Given that the AD-associated APP gene is on chromosome 21, and that rare DS individuals who lack a third copy of APP do not develop AD [6], overexpression of APP and accumulation of the amyloid β-protein (Aβ) are considered the main drivers of AD in DS.

Early clinical diagnosis of AD in people with DS is complex and challenging because patients with DS have a pre-existing intellectual disability, the extent of which varies from person to person. Reliable AD-specific biomarkers would greatly assist early diagnosis of AD in DS, and could facilitate clinical care planning, and timely treatment with disease-modifying AD therapies which may soon become available [7, 8]. Measurement of Aβ and tau by their detection in CSF using immunoassays or visualization of deposited proteins using PET imaging can reliably detect AD in at-risk individuals [9–11]. However, PET imaging is expensive and its application outside of clinical research remains limited. Collection of CSF, although routine in certain countries, remains unpopular with patients, especially if required more than once. Lumbar puncture and PET scans are particularly challenging in a vulnerable population such as people with DS. In contrast, collection of blood would be significantly easier for individuals with DS, making blood-based biomarkers of AD in DS the preferred option.

Post-mortem studies of brains from individuals with DS reveal that in general, diffuse amyloid plaques appear in the late teens, and tau pathology emerges after age 35 [12, 13]. Whether blood-based biomarkers of AD evolve in a similar temporal pattern is not yet clear. Prior studies of putative AD biomarkers examined restricted age groups [14–16], and earlier studies employed suboptimal assays [17]. Most previous investigations on AD biomarkers in DS were limited to analysis of plasma Aβ.

Conclusions: High levels of Aβ42 and tau in both young controls and DS suggest these proteins are produced by normal physiological processes, whereas the changes seen in later life are consistent with emergence of pathological alterations. These plasma biomarker results are in good agreement with prior neuropathology studies and indicate that the third and fourth decades (i.e., 20 to 40 years of age) of life are pivotal periods during which AD processes manifest in DS. Application of the assays used here to longitudinal studies of individuals with DS aged 20 to 50 years of age should further validate the use of these biomarkers, and in time may allow identification and monitoring of people with DS best suited for treatment with AD therapies.

Keywords: Alzheimer’s disease, Amyloid, Down syndrome, Dementia, Neurofilament light, Simoa

Material and methods
Participants
**PRECISION study cohort**
Blood was collected from ten healthy volunteers twice a day at 2 day intervals over a 5 day period. Participant
characteristics are presented in Supplemental Table 1 (Additional file 1). On each day, blood was collected in the morning between 7 and 10 am and in the evening between 4 and 7 pm. The average time between blood draws on the same day was 8.4 ± 1.0 h. Participants had fasted for at least 10 h prior to morning blood draws (average fasting period 11.2 ± 1.0 h), but fasting was not requested for blood collection done in the evening. Blood was collected into 8 mL ethylenediaminetetraacetic acid (EDTA)-treated tubes by peripheral venipuncture with a 21G butterfly needle. Plasma was processed as quickly as possible, and the average time between venipuncture to plasma isolation was 19 min. Specimens were centrifuged at 2000×g for 10 min at 4 °C, and the supernatant was carefully removed and aliquoted into 500 μL lots in 1.5 mL Eppendorf protein lobe tubes and stored at −80 °C. The study was conducted in accordance with the local clinical research regulations and approved by the Partners Institutional Review Board (Walsh, BWH2017P000259), and all participants gave written informed consent.

**Down syndrome and control participants**

Plasma samples were taken from 100 people with Down syndrome. Samples were obtained from three centers. The bulk of the samples (n = 82) were collected prospectively at the Massachusetts General Hospital Down Syndrome Program. Additional samples came from the Center for Neuroimaging of Aging and Neurodegenerative Disease of the Massachusetts General Hospital (n = 13) and the LonDownS Consortium at King’s College London (n = 5). Fasting was not required, and the time of day at which blood was collected was not prescribed.

**Massachusetts General Hospital Down Syndrome Program**

Participants with Down syndrome and/or their legal guardians were consented during outpatient visits at the Massachusetts General Hospital Down Syndrome Program. The protocol was approved by the Partners Human Research Committee. Blood was drawn from the antecubital vein with a 21G needle and collected into EDTA-treated tubes. Plasma was isolated by centrifugation at 2000×g at 4 °C for 10 min, and aliquots processed and stored as described for the PRECISION cohort.

**Center for Neuroimaging of Aging and Neurodegenerative Disease of the Massachusetts General Hospital**

Participants with DS were recruited from the MGH Down syndrome research database. Experimental procedures were explained, and signed informed consent/assent was obtained prior to participation. The protocol was approved by the Institutional Review Board (2018P000898). Blood collection and processing was performed as described for the PRECISION study cohort.

**LonDownS Consortium**

Participants with DS were also recruited as a part of the LonDownS Consortium’s cohort study of Alzheimer’s disease [27]. Ethical approval was obtained from the North West Wales Research Ethics Committee (13/WA/0194). Written informed consent was obtained if participants could consent for themselves; otherwise, a consultee was asked to approve the individual’s inclusion. Blood samples were collected in EDTA tubes and processed within 2 h. Plasma was prepared by centrifuging samples for 10 min at 2200×g at 4 °C; the supernatant was aliquoted and stored at −80 °C.

**Boston Children’s Hospital and Partners Biobank**

Specimens from age- and sex-matched control subjects were obtained from the Precision Link Biobank at Boston Children’s Hospital (BCH) and the Biobank at Partners HealthCare in Boston (MA, USA). Controls had no history of diseases of the central nervous system. Specifically, there was no evidence of brain tumor, normal pressure hydrocephalus, stroke, severe brain trauma, brain surgery, epilepsy, encephalitis, or dementia. Included participants were free of acute infectious disease.

Precision Link Biobank participants (n = 67) were enrolled throughout the hospital, across diverse clinical settings. In-person informed consent was obtained from all participants enrolling in the Biobank and provides permission to (1) access electronic health record data for research, (2) collect and use residual specimens produced as by-products of routine care, and (3) share de-identified data and specimens outside of the institution. Participants provided a 4 mL blood sample for research use. Whole blood was collected in EDTA tubes, centrifuged at 2000×g for 10 min at room temperature, with plasma removed and aliquoted into 0.5 mL microcentrifuge tubes. Aliquots were stored at −80 °C in the Biobank Core Lab facility until requested. The Precision Link Biobank initiative is approved by the BCH Institutional Review Board (P00000159).

Additional samples (n = 33) and health information were obtained from the Partners HealthCare Biobank, a repository of consented patient samples at Partners HealthCare. The Partners HealthCare Biobank is approved by the Institutional Review Board (2009P002312). Blood was collected, and plasma generated as described above.

**Single molecule array immunoassays**

Levels of Aβ42, NT1 tau, and Nfl were quantified using single molecule array (Simoa) assays. All assays were performed by the same operator and conducted on the same automated HD-1 analyzer (Quanterix, Billerica,
MA). Consumables and reagents other than certain antibodies were obtained from Quanterix. The NT1 tau assay was developed in-house [21], and commercial kits were used to measure Aβ42 and NFL.

**NT1**
This is a 3-step assay capable of detecting all forms of tau which contain residues 6–198 [21]. BT2 (194-198, Thermo, Waltham, MA, USA) was conjugated onto paramagnetic beads at 2 mg/mL and used for capture. Biotinylated Tau12 (6-13, Merck Millipore, Darmstadt, Germany) was used for detection.

The optimal plasma dilution (1:4) to minimize matrix effects was determined previously [21]. Plasma samples were thawed on ice, centrifuged at 14,000×g and used for capture. Biotinylated Tau12 (6-13, Merck Millipore, Darmstadt, Germany) was used for detection.

The Lower limit of quantitation (LLoQ) defined as the lowest standard (i) with a signal higher than the average signal for the blank plus 9 SDs, and (ii) allowed a percent recovery ≥ 100 ± 20%. In 4 runs over 4 days, the LLoQ was 0.25 pg/mL. The average percent coefficient of variation (%CV) of all samples measured in the study was 13.8%. Assay characteristics including selectivity, dilution linearity, and spike and recovery were reported previously [21].

**Aβ42 and NFL**
The Simoa® Aβ42 Advantage (Quanterix, Billerica, MA, USA) and Simoa™ NF-light® Advantage (Quanterix, Billerica, MA, USA) kits were used according to the manufacturer’s instructions. Reagents from a single lot were used for analysis of all specimens from either the PRECISION study cohort or the Down syndrome study cohort. To determine the optimal dilution factor, plasma samples from 73 healthy donors were diluted 1:4 and 1:8 and analyzed for Aβ1-42 and NFL, and the highest dilution factor that allowed reliable quantification of samples was used. Thereafter, specimens were diluted 1:8 for Aβ42 and 1:4 for NFL. As with specimens for the NT1 assay, plasma was centrifuged at 14,000×g for 4 min; the upper 90% transferred to a new Eppendorf protein lobind tube and diluted 1:4 with Tau 2.0 sample diluent reagent (Quanterix, Billerica, MA). Samples, standards, and blanks were analyzed at least in duplicate.

Statistical analyses
Statistical analyses were carried out using GraphPad Prism, version 8 (LaJolla, CA, USA), and Stata, version 15.1 (Stata Corp., College Station, TX, USA). The effect of daytime (morning vs. evening blood draws) and different weekdays (day 1 vs. day 3 vs. day 5) on plasma biomarker levels was assessed using linear mixed models (“mixed”). Both variables were included as fixed effects, whereas subjects were used as random effects. To assess goodness of fit, we included both variables in a stepwise process and compared Akaike information criterion (AIC) of the respective models (“estat ic”). Tests on estimated coefficients were performed using the Wald test postestimation command (“test”). Differences of biomarker levels between DS and controls for specified age ranges were assessed using a paired t test (for normally distributed data) or a Wilcoxon signed-rank test (for non-normally distributed data). p values were adjusted for multiple testing by Bonferroni correction. Additionally, piecewise linear regression using hockey-stick regression was applied to model the effect of age on plasma biomarker levels in DS and controls (and differences between both groups) [28]. The slopes of both regression lines and the change-point where both regression lines meet were estimated using the “nl hockey” function. From specimens of DS and age-matched control participants, 10 out of 600 measurements (1.7%, 7 for the NT1 tau and 3 for the NFL assay, see Additional file 1: Supplemental Table 2 for raw data) were below the LLoQ of the respective assay (determined as described above), and for statistical analysis, these samples were assigned values equal to the LLoQ of the assay. Statistical analysis was repeated with the actual readings of these 10 measurements, but produced similar results. The significance threshold was set to a two-sided p ≤ 0.05.

**Results**
**Plasma Aβ42, NT1, and NFL levels are stable over a 5 day period and are not influenced by the time of day when blood is collected**
The usefulness of any biomarker is, among other in vivo factors, influenced by whether (i) remains constant over a reasonable period of time, (ii) is altered by diurnal factors, and (iii) requires pre-sampling fasting. Here, we sought to examine biomarkers of amyloid, tau, and neurodegeneration [29] in plasma of individuals with DS across the first seven decades of life. Before analyzing precious clinical samples, we conducted experiments to test the stability of analytes to be measured, namely Aβ42, NT1 tau, and NFL. Blood was collected from 10 healthy volunteers on days 1, 3, and 5. On each collection day, blood was obtained at two time points: (i) morning (after an overnight fasting) and (ii) evening.
This design was employed to account for clinical practice in an outpatient setting in which patients are asked either to donate blood in the morning after overnight fasting, or to attend clinic later in the day without any dietary restrictions. Figure 1 shows the measured concentrations of Aβ42, NT1 tau, and NfL in the morning (red circles) and in the evening (blue squares). Spaghetti blots of individual measurements from all 10 healthy volunteers are presented in Supplemental Figures 1–3 (Additional file 2). Measurements for all three analytes in specimens collected in the morning and in the evening on three different days in 1 week were highly similar (Fig. 1). There was no statistically significant effect of time of day (morning vs. evening), and analyte levels were stable across the 5-day sampling period (day 1 vs. day 3 vs. day 5). The %CVs of measurements obtained on the morning of day 1, day 3, and day 5 in the same individual for Aβ42, NT1 tau, and NfL were 3.8% (range 0.9–6.2%), 9.3% (range 1.3–20.3%), and 7.3% (range 0.4–15.0%), respectively. Comparable %CVs were observed for measurements in the evening (Table 1). Collectively, these results demonstrate that the forms of Aβ, tau, and NfL in plasma measured by the Aβ42, NT1 tau, and NfL assay are stable, and do not appear to be influenced by diurnal and dietary factors. These findings have relevance both to the current study and for all studies measuring these analytes. Our study involved subjects from vulnerable populations (including individuals with DS, neonates, and young children) for whom it would be unreasonable to request overnight fasting for a research study, or to coordinate blood collection at a specific time of day. Thus, it is important that the measured analytes are not influenced by time of day or dietary intake.

Aβ1-42, NT1, and NfL plasma concentrations depend on age in Down syndrome individuals compared to controls

To study age-dependent changes of plasma AD biomarkers in DS, samples were obtained from 100 people with DS aged 3 months to 68 years. One hundred age- and sex-matched participants free of neurological disease served as controls (see Table 2 for participant characteristics).

Individual results for all 3 analytes are presented in Supplemental Table 2 (Additional file 1). Concentrations of Aβ42 were higher in individuals with DS than controls across the entire age range (Fig. 2 a, d and Table 3). In the youngest age group (0–10 years), mean Aβ42 concentrations were approximately 1.6-fold higher in DS individuals compared to controls (45.3 vs. 28.1 pg/mL, p < 0.001), but the differences between plasma Aβ1-42 levels in individuals with DS and controls declined with increasing age (Fig. 3a, d). At approximately 30 years of age, Aβ42 levels reached a steady level of ~22 pg/mL for individuals with DS and ~15 pg/mL for controls. In the oldest age group (>50 years), mean Aβ42 concentrations were ~1.4-fold higher in individuals with DS compared to controls (22.7 pg/mL vs. 16.6 pg/mL, p = 0.07).

For NT1 tau, levels were highest in children and fell with age in both the DS and control groups (Fig. 2b, e and Table 3). In general, the levels of NT1 tau in DS and controls broadly overlapped, but tended to diverge after the age of 30 (Fig. 3b, e and Table 3). Specifically, in individuals with DS 50 years and older, NT1 levels were significantly increased compared to controls (7.0 vs. 4.0 pg/mL, p = 0.042) (Fig. 3e, Table 3).

For the first three decades of life, plasma NfL levels were relatively constant and were similar in DS and controls (Fig. 2c, f and Fig. 3c, f, Table 3). In subjects over...
30 years of age, NfL levels increased in both controls and DS, but the increase was considerably greater for people with DS. Specifically, NfL levels were significantly increased in individuals with DS compared to controls at ages 40 and older (41–50 years, 15.9 vs. 8.3 pg/mL, \( p = 0.001 \); > 50 years, 31.0 vs. 11.7, \( p = 0.023 \)) (Fig. 2f, Table 3).

We also applied more sophisticated statistical models in an attempt to better understand differences in the age-dependent changes in DS versus controls. Specifically, we used piecewise linear regression to determine time points of slope changes in DS and controls (Additional file 1: Supplemental Table 3 and Additional file 2: Supplemental Figure 4). Minimum levels of A\( \beta \)42 in DS were reached at 26 years, whereas in controls, the minimum occurred at 15 years. In DS, the infliction point for NT1 was 17 years, and in controls 29 years, and only in old age was NT1 higher in DS individuals than controls. NfL levels increased with age in both DS and control individuals, but the slope was much steeper in DS compared to controls (1.05 pg/mL vs. 0.19 pg/mL per year). While these analyses suggest some important trends, it is important to note that the wide confidence intervals associated with estimates for time points of slope change make it problematic to assign reliable change-points.

**Discussion**

Here, we analyzed changes in biomarkers related to 3 primary features of AD and AD in DS: amyloid, tau, and neurodegeneration [29]. In the absence of large longitudinal cohorts, we gathered specimens from 100 DS individuals aged from 3 months to 68 years and compared their values with those of age- and sex-matched controls. We found that A\( \beta \)42 levels were higher in DS than in controls, regardless of age. In both DS and controls, A\( \beta \)42 levels were highest in neonates. NT1 tau levels were similar in DS and controls across all ages, except for older ages when NT1 tau was higher in DS than controls. For both DS and controls, NfL levels were relatively low in age groups up to ~30 years, whereas in older age groups, NfL was higher and the increase was greater in DS than in controls.

As expected for individuals with 3 copies of the APP gene (and consistent with prior studies [17, 30–32]), we

| Table 1 Biological variation of analytes |
|----------------------------------------|
| Assay Daytime | Mean ± SD (range) level for all 10 donors (pg/mL) | Mean ± SD (range) intra-subject %CV for all 10 donors |
|---------------|--------------------------------------------------|--------------------------------------------------|
| A\( \beta \)42 Morning | 20.07 ± 2.81 (16.1–26.2) | 3.8 ± 1.9% (0.9–6.2%) |
| A\( \beta \)42 Evening | 20.47 ± 2.89 (16.3–25.1) | 5.1 ± 3.4% (1.0–12.2%) |
| NT1 tau Morning | 2.31 ± 0.49 (1.4–3.4) | 9.3 ± 5.3% (1.3–20.3%) |
| NT1 tau Evening | 2.26 ± 0.51 (1.5–3.5) | 8.7 ± 7.3% (1.1–26.5%) |
| NfL Morning | 7.20 ± 3.30 (2.4–13.4) | 7.3 ± 4.7% (0.4–15.0%) |
| NfL Evening | 7.09 ± 3.03 (2.5–13.7) | 8.9 ± 4.3% (3.3–17.1%) |

Abbreviations: SD standard deviation, %CV percentage coefficient of variation

| Table 2 Demographics of DS and controls |
|----------------------------------------|
| Age groups (in years) | Down syndrome | Control |
| Age in years mean ± SD | Age in years mean ± SD |
| Mean age (year) 0–10 | 4.9 ± 2.9 | 5.0 ± 2.9 |
| 11–20 | 16.2 ± 3.1 | 16.3 ± 3.2 |
| 21–30 | 24.1 ± 2.8 | 24.0 ± 3.2 |
| 31–40 | 35.7 ± 2.9 | 35.5 ± 3.0 |
| 41–50 | 45.4 ± 3.6 | 45.2 ± 3.3 |
| > 50 | 57.1 ± 5.6 | 57.1 ± 5.6 |

| Age group (in years) N | Number of females (% of total) | Number of females (% of total) |
| Sex (female) 0–10 | 15 (50.0) | 15 (50.0) |
| 11–20 | 10 (43.5) | 10 (43.5) |
| 21–30 | 4 (26.7) | 4 (26.7) |
| 31–40 | 4 (40.0) | 4 (40.0) |
| 41–50 | 4 (30.8) | 4 (30.8) |
| > 50 | 1 (11.1) | 1 (11.1) |

Abbreviation: SD standard deviation
observed higher plasma Aβ42 levels in individuals with DS compared to controls. In the first decade of life, a time when there is little amyloid deposition [33, 34], plasma Aβ42 levels were on average a little higher (~1.6 fold) in DS than the expected 1.5-fold elevation due to gene dosage \((p = 0.03)\). Why this should be is unclear, but it is worth noting that several AD risk factors are encoded on chromosome 21 [2] and these might contribute to either enhanced amyloidogenic processing of APP [35, 36] or reduced degradation of Aβ [37]. Also, neuronal Aβ production is activity dependent [38], and in DS, there is evidence of aberrant hyperactivity during development and early life [39] that could contribute to higher Aβ levels.

Aβ42 levels tended to fall with age in both individuals with DS and controls, but the relative decrease was greater in DS. There was a strong tendency for the DS/control Aβ42 ratio to be lower in the oldest group (>50 years) compared to youngest group (0–10 years); however, this did not reach statistical significance (1.6 vs. 1.4, \(p = 0.08\)). Nonetheless, the trend is consistent with the notion that Aβ42 is prone to aggregate and becomes trapped in accumulating plaques and is in line with multiple AD studies linking falling CSF and plasma Aβ42 with increased cerebral amyloid deposition [40, 41]. However, prior studies examining the association of plasma Aβ42 with age in DS have yielded conflicting results with reports of increased [42], decreased [43], and unchanged Aβ42 levels [14, 31, 44]. But previous studies were not designed to look at the effect of age across a broad age span. We found that plasma Aβ42 levels fell sharply in the first 3 decades of life in individuals with DS, but were relatively stable in the age range from 31 to 68 years. Our results from a broad age range of individuals (3 months to 68 years) provide the perspective to better understand what had formerly appeared discordant results, that is, decreasing Aβ42 levels in younger DS individuals [43] but relatively stable levels in older DS individuals [14, 31, 44].

Human plasma is a complex matrix, components of which can interfere with immunoassays. One means of overcoming matrix interference is to dilute samples so as to reduce interfering plasma components to a level below which they no longer interfere. This requires that...
the assays employed are sufficiently sensitive to allow dilutions necessary to preclude matrix interference. Here, we employed ultra-sensitive assays and evaluated the maximum dilution that allowed consistent detection of analytes across a large number of human samples. For Aβ42, only a few studies [27, 32, 45, 46] have used such ultra-sensitive techniques.

In contrast to Aβ, only a handful of studies have attempted to measure tau in plasma of DS individuals. Extracellular tau is molecularly complex [20–22], and different assays detect distinct populations of tau isoforms, complicating comparisons of results obtained using different assays. Here, we utilized our in-house NT1 tau assay which we have previously shown to be capable of detecting forms of tau that are significantly elevated in plasma of patients with AD-MCI and mild AD [21]. Like Aβ42, NT1 detected tau was highest at early age (0–10 years). NT1 levels fell between 11 and 30 years but thereafter increased. This pattern is a mirror image of the Aβ42 results, with both exhibiting pivotal changes between 20 and 40 years.

NfL, a now widely validated marker of neurodegeneration [18], was relatively low in early life, but in both controls and DS, NfL increased steadily after age 30. Importantly, NfL levels in plasma of individuals with DS started to diverge from control levels in the 31–40-year age group and were most different in the two oldest age groups.

Collectively, our findings demonstrate that plasma measures of amyloid, tau, and neurodegeneration change with age and that the relative differences in these markers are greatest in the 31–40-, 41–50-, and over 50-year age groups. In our study cohort, elevated concentrations of NfL and NT1 measured tau in older individuals with DS are consistent with the following: (i) recent cross-sectional studies that found increased plasma NfL and tau in prodromal and AD dementia in people with DS [32, 47], and (ii) an increasing prevalence of AD in older individuals with DS [4, 5]. Notwithstanding the identification of these important trends, our results indicate that it will be impractical to use a single time point measurement of these biomarkers to diagnose AD in DS. Rather, our data support longitudinal assessment of these markers to further evaluate their potential to predict onset of disease.

A particular strength of this study is the use of a relatively large number of DS individuals (n = 100) and age- and sex-matched controls (n = 100) with a broad age range (3 months to 68 years). Another strength is the use of analytically validated methods and testing conditions. The major weaknesses of our study include the fact that the study is cross-sectional and not longitudinal, the use

| Analyte     | Age group (in years) | Down syndrome | Control | p value* |
|-------------|----------------------|---------------|---------|----------|
| Aβ42 (pg/mL)| 0–10                 | 45.3 ± 2.1    | 28.1 ± 1.6 | <0.001   |
|             | 11–20                | 31.8 ± 2.0    | 16.2 ± 1.2 | <0.001   |
|             | 21–30                | 28.1 ± 2.3    | 15.7 ± 0.8 | <0.001   |
|             | 31–40                | 21.4 ± 1.3    | 15.0 ± 1.5 | 0.014    |
|             | 41–50                | 22.7 ± 0.7    | 14.7 ± 0.6 | <0.001   |
|             | > 50                 | 22.7 ± 1.8    | 16.6 ± 0.8 | n.s.     |
| NT1 tau (pg/mL) | 0–10             | 8.3 ± 0.5     | 7.9 ± 0.8  | n.s.     |
|             | 11–20                | 4.3 ± 0.5     | 5.6 ± 0.5  | n.s.     |
|             | 21–30                | 4.3 ± 0.4     | 4.6 ± 0.4  | n.s.     |
|             | 31–40                | 4.2 ± 0.6     | 3.2 ± 0.6  | n.s.     |
|             | 41–50                | 4.6 ± 0.4     | 3.2 ± 0.3  | n.s.     |
|             | > 50                 | 7.0 ± 0.8     | 4.1 ± 0.2  | 0.042    |
| NfL (pg/mL) | 0–10                 | 7.5 ± 0.5     | 6.3 ± 0.6  | n.s.     |
|             | 11–20                | 5.1 ± 0.4     | 3.6 ± 0.3  | 0.010    |
|             | 21–30                | 6.7 ± 0.4     | 5.4 ± 0.9  | n.s.     |
|             | 31–40                | 10.2 ± 1.6    | 6.8 ± 1.3  | n.s.     |
|             | 41–50                | 15.9 ± 1.0    | 8.3 ± 1.0  | 0.001    |
|             | > 50                 | 31.0 ± 6.0    | 11.7 ± 1.1 | 0.023    |

Mean concentrations ± SEM
*p value adjusted for multiple comparisons in age strata by Bonferroni correction
of controls from a biobank, and that we did not include cognitive assessments. Future studies should collect clinical information, such as cognitive measures, APOE status, and concomitant medication, and it may be useful to measure other alloforms of Aβ so as to calculate ratios of different Aβ species (e.g., Aβ42/40, Aβ42/38).

Conclusions

Viewed together, the trajectories of all three biomarkers point towards important changes after the third decade of life in people with DS. During that period, Aβ42 in DS falls considerably and NT1 and NfL levels rise steadily. In order to identify individuals with DS who would most benefit from secondary prevention treatments, future prospective longitudinal studies should focus on the critical age span between 30 and 50 years measuring both biomarker changes and cognition. Our successful use of sensitive and dynamic plasma analytes reflecting the cardinal features of AD is particularly salient for people with DS, given the ethical challenges of trying to use CSF or brain imaging to monitor their temporal progression into AD.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13195-020-00593-7.

Additional file 1: Table S1. Demographics of the PRECISION study cohort. Table S2. Individual results of plasma Aβ42, NT1 tau, and NfL in Down syndrome and controls. Table S3. Change-point regression for association of age with plasma biomarker levels.

Additional file 2: Figure S1. Plasma Aβ42 levels are stable when measured in the same subjects over a 5 day period. Figure S2. Plasma NT1 tau levels are stable in the same subjects over a 5 day period. Figure S3. Plasma NfL levels are stable in the same subjects over a 5 day period. Figure S4. Prediction of biomarker changes by age using piecewise linear regression.

Abbreviations
Aβ42: Amyloid β-protein ending at amino acid 42; AD: Alzheimer’s disease; APOE: Apolipoprotein E; APP: Amyloid precursor protein; CSF: Cerebrospinal fluid; DS: Down syndrome; EDTA: Ethylenediaminetetraacetic acid; LLoQ: Lower limit of quantitation; NT1 tau: N-terminal tau 1 assay (detects forms of tau containing at least residues 6–198); NfL: Neurofilament light; PET: Positron emission tomography; Simoa: Single molecule array; %CV: Percent coefficient of variation.

Acknowledgements

We are grateful to the blood donors and their families and clinician colleagues for referring patients and collecting blood. We thank Partners
HealthCare Biobank for providing samples and health information data. We also acknowledge material and data support from the Precision Link Biobank for Health Discovery at Boston Children’s Hospital.

**Authors’ contributions**: DMW conceived the project and designed and supervised the research. DMW and DM wrote the manuscript. BS assisted in the design of the experiments. DM wrote the study protocols, collected the samples, carried out the experiments, analyzed the data, and prepared the figures. WL assisted with the processing and analysis of samples. AS supplied the archived samples. FL, HDR, DJS, and BS, AT, and VP provided the samples. RiG assisted with the statistical analysis. All the authors critically assessed and contributed to the writing of the manuscript. The authors read and approved the final manuscript.

**Funding**: DMW is an Alzheimer’s Association Zenith fellow, and this work was made possible by support to DMW from the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation, and the Foundation for Neurologic Diseases, and to AS from the Wellcome Trust Strategic Award (grant number: 098330/2/12/Z) conferred upon The London Down Syndrome (LonDownS) Consortium. DM is supported by a Research Fellowship from the German Research Foundation (DFG ME 4858/1-1).

**Availability of data and materials**: Raw data of plasma measurements in DS and controls are reported in Supplemental Table 2 (Additional file 1). All other data supporting the conclusions of this manuscript will be made available by the corresponding authors, without undue reservation, to any qualified researcher. All materials used in the publication are commercially available.

**Ethics approval and consent to participate**: Signed informed consent/assent was obtained prior to participation from all individuals. Protocols were approved by the Internal Review Board of all participating research sites (Partners Institutional Review Board, BCH Institutional Review Board, North West Wales Research Ethics Committee).

**Consent for publication**: Not applicable.

**Competing interests**: DMW is an employee of Biogen Inc. AS has consulted for/or been an investigator on studies sponsored by the following companies: Hoffmann-La Roche Ltd, ONO Pharma, Aelis Farma, AC-Immune, and ProMIS Neurosciences. DJS is a director and consultant to Prothena Biosciences. BS occasionally consults on the topic of Down syndrome through Gerson Lehrman Group. He receives remuneration from Down syndrome non-profit organizations for speaking engagements and associated travel expenses. BS receives annual royalties from Woodbine House, Inc., for the publication of his book, *Fasten Your Seatbelt: A Crash Course on Down Syndrome for Brothers and Sisters*. Within the past 2 years, he has received research funding from F. Hoffmann-La Roche, Inc, and LuMind Research Down Syndrome Foundation to conduct clinical trials for people with Down syndrome. BS is occasionally asked to serve as an expert witness for legal cases where Down syndrome is discussed. BS serves in a non-paid capacity on the Honorary Board of Directors for the Massachusetts Down Syndrome Congress and the Professional Advisory Committee for the National Center for Prenatal and Postnatal Down Syndrome Resources. BS has a sister with Down syndrome. None of the other authors have biomedical financial interests or potential conflicts of interest.

**Author details**: 1Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, 60 Fenwood Road, Boston, MA 02115, USA. 2Department of Neurodegenerative Diseases, Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. 3Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA, USA. 4Department of Forensic and Neuropsychological Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK. 5Division of Psychiatry, University College London, London, UK. 6Department of Neurology, Massachusetts General Hospital and McLean Hospital, and Harvard Medical School, Boston, MA, USA. 7Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA. 8Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA. 9Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

**Received**: 25 November 2019 Accepted: 6 March 2020

**Published online**: 19 March 2020

**References**

1. Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down's syndrome. Lancet Neurol. 2016;15:622–36.
2. Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizzeti D, Tybulewicz VL, Fisher EM, Strydom A. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16:564–74.
3. McCarron M, McCaillon P, Reilly E, Dunne P, Carroll R, Mulryan N. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J Intell Disabil Res. 2017;61:843–52.
4. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol. 1989;46:849–53.
5. Evenhuis HM. The natural history of dementia in Down's syndrome. Arch Neurol. 1990;47:263–7.
6. Doran E, Keator D, Head E, Phelan MJ, Rini K, Barrio JR, Small GW, Potkin SG, Lott IT. Down syndrome, partial trisomy 21, and absence of Alzheimer's disease: the role of APP. J Alzheimers Dis. 2017;56:459–70.
7. Reports of My Death Are Greatly Exaggerated. Signed, Aducanumab [https://www.alzforum.org/news-research-reports/my-death-are-greatly-exaggerated-signed-aducanumab].
8. Topline Results: 18 Months of BAN2401 Might Work [https://www.alzforum.org/news-research-news/topline-results-18-months-ban2401-might-work].
9. Blennow K. A review of fluid biomarkers for Alzheimer's disease: moving from CSF to blood. Neurol Ther. 2017;6:15–24.
10. Handsels RLH, Vos SJ, Kramberger MG, Jelic V, Blennow K, van Buchem M, van der Flier W, Freund-Levi Y, Hampel H, Olde Rikkert M, et al. Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimers Dement. 2017;13:903–12.
11. Vallemagne VL, Doré J, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14:225–36.
12. Davidson YS, Robinson A, Prashar VP. Mann DMA. The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome. Acta Neurochirupathol Commun. 2018:5;56.
13. Mann DM. Cerebral amyloidosis, ageing and Alzheimer’s disease: a contribution from studies on Down’s syndrome. Neurobiol Aging. 1989;10: 397–9 discussion 412-394.
14. Jones EL, Hanney M, Francis PT, Ballard CG. Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci Lett. 2009;451: 162–4.
15. Abdel-Meguid IS, Abdel-Salam E, Latif DMA, Korra S, Ismaiel A. Markers of neural degeneration and regeneration in Down syndrome patients. Egyptian J Med Human Genet. 2013;14:449–53.
16. Conti E, Gallimberti G, Piazza F, Raggi ME, Ferreroe C. Increased soluble APPAlpha, Abeta 1-42, and anti-Abeta 1-42 antibodies in plasma from Down syndrome patients. Alzheimer Dis Assoc Disord. 2010;24:96–100.
17. Alhajraf F, Ness D, Hye A, Strydom A. Plasma amyloid and tau as dementia biomarkers in Down syndrome: systematic review and meta-analyses. Dev Neurobiol. 2019;79(7):684–98.
18. Bidel C, van Weering WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeno JC, Andreasen U, Axelson M, Backstrom DC, Bartos A, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019. https://doi.org/10.1001/jamaneurol.2019.1534. [Epub ahead of print].
19. Kuhle J, Baro C, Andreasen U, Deffais T, Lindberg R, Sandellus A, Liman V, Norgren N, Blennow K, Zetterberg H. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunosay and Simoa. Clin Chem Lab Med. 2016;54:1655–61.
20. Kannert D, Cantlon A, Muratore CR, Jin M, O’Malley TT, Lee G, Young-Pearse TL, Selkoe DJ, Walsh DM. C-terminally truncated forms of tau, but not full-
length tau or its C-terminal fragments, are released from neurons independently of cell death. J Neurosci. 2015;35:10851–61.

21. Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M, Percival-Allwyn J, Schultz A, Properz M, Johnson K, et al. Learnings about the complexity of extracellular tau ad development of a blood-based screen for Alzheimer’s disease. Alzheimers Dement. 2019;15:487–96.

22. Cicogna C, Brinkmalm G, Wahlgren J, Portellus E, Gobom J, Cullen NC, Hansson O, Parnetti L, Constantinescu R, Wildsmith K, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease. Acta Neuropathol. 2019;137:279–96.

23. Mengel D, Janelidze S, Glynn RJ, Liu W, Hansson O, Walsh DM. Plasma NfL and NTI predict conversion of MCI/SC to AD dementia. unpublished results.

24. Deters KD, Risacher SL, Kim S, Nho K, West JD, Blennow K, Zetterberg H, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ. Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. 2017;58:1245–54.

25. Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stromrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, et al. Plasma tau in Alzheimer disease. Neurology. 2016;87:1827–35.

26. Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673–84.

27. Startin CM, Ashton NJ, Hamborg S, Hithersay R, Wiseman FK, Mok KY, Hardy J, Lleo A, Lovestone S, Parnetti L, et al. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease. Alzheimers Res Ther. 2019;11:26.

28. Petersen ME, O’Byant SE. Blood-based biomarkers for Down syndrome and Alzheimer’s disease: a systematic review. Dev Neurobiol. 2019;79(7):699–710.

29. Schupf N, Patel B, Silverman W, Zigman WB, Zhong N, Tycko B, Mehta PD, Mayeux R. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett. 2001;301:199–203.

30. Forteza J, Carmona-Tagui M, Benemaj B, Fernández S, Videla L, Baroeta I, Alcolea D, Pegasueros J, Munoz L, Belbin O, et al. Plasma biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17:860–9.

31. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol. 1985;17:278–82.

32. Lemere CA, Bluzstajn JK, Yamaguchi H, Wisniewski T, Saído TC, Sellke DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996;3:16–32.

33. Wiegell J, Gong CX, Hwang YW. The role of DyrK1A in neurodegenerative diseases. FEBS J. 2011;278:236–45.

34. Bianca C, Shaw DM, Belfiore R, Gokhale V, Shaw AY, Foley C, Smith B, Hulme C, Duncleave T, Meechouvet B, et al. DyrK1 inhibition improves Alzheimer’s disease-like pathology. Aging Cell. 2017;16:1146–54.

35. Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson D, Bandopadhuy U, Jang Y, et al. Reversal of autophagy dysfunction in the TgN(RD8) mouse model of Alzheimer’s disease ameliorates amyloid pathologies and memory deficits. Brain. 2011;134:258–77.

36. Cittro JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepf OD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913–22.

37. Aarya R, Kabra M, Gulati S. Epilepsy in children with Down syndrome. Epileptic Disord. 2011;13:1–7.

38. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, Fowler C, Li QX, Martins R, Rowe C, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554:249–54.

39. Palmqvist S, Janelidze S, Stromrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 2019. https://doi.org/10.1001/jamaneurol.2019.1632. [Epub ahead of print].

40. Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, Mayeux R. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007;64:1007–13.

41. Mehta PD, Mehta SP, Fedor B, Patrick BA, Emmerling M, Dalton AJ. Plasma amyloid beta protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett. 2003;342:55–8.

42. Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord. 2009;23:315–8.

43. Lee NC, Yang SY, Chieh JJ, Huang PT, Chang LM, Chiu VN, Huang AC, Chien YH, Hwu WL, Chiu MJ. Blood beta-amyloid and tau in Down syndrome: a comparison with Alzheimer’s disease. Front Aging Neurosci. 2016;8:316.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.